AIMS: Increasing evidence supports the participation of metabolic syndrome and insulin resistance in the pathogenesis of pre-eclampsia. Copeptin is co-synthesized with vasopressin and is a new and promising novel marker of metabolic syndrome and insulin resistance. Our aim was to investigate copeptin levels in normotensive pregnant, mild and severe pre-eclamptic women. MATERIALS AND METHODS: We included 96 pregnant women who received antenatal and obstetric care at the perinatology clinic of our hospital. They were divided into three groups: women with normal ongoing pregnancy (n=32), those with mild pre-eclampsia (n=32) and those with severe pre-eclampsia (n=32). Doppler velocimetry measurements of the uterine and umbilical arteries were performed for each patient. Plasma levels of copeptin were quantified with enzyme-linked immunosorbent assay. RESULTS: Plasma levels of copeptin were 0.31±0.09 ng/mL in the normotensive pregnant group, 0.62±0.16 ng/mL in the mild pre-eclamptic group and 0.85±0.18 ng/mL in the severe pre-eclamptic group (P<0.001). Copeptin levels in pre-eclamptic patients with abnormal Doppler velocimetry were significantly higher than in those with normal Doppler velocimetry. CONCLUSIONS: These results suggest that increased maternal levels of copeptin may be involved in the pathogenesis of pre-eclampsia and it may be useful in the assessment of the severity of the disease.
AIMS: Increasing evidence supports the participation of metabolic syndrome and insulin resistance in the pathogenesis of pre-eclampsia. Copeptin is co-synthesized with vasopressin and is a new and promising novel marker of metabolic syndrome and insulin resistance. Our aim was to investigate copeptin levels in normotensive pregnant, mild and severe pre-eclamptic women. MATERIALS AND METHODS: We included 96 pregnant women who received antenatal and obstetric care at the perinatology clinic of our hospital. They were divided into three groups: women with normal ongoing pregnancy (n=32), those with mild pre-eclampsia (n=32) and those with severe pre-eclampsia (n=32). Doppler velocimetry measurements of the uterine and umbilical arteries were performed for each patient. Plasma levels of copeptin were quantified with enzyme-linked immunosorbent assay. RESULTS: Plasma levels of copeptin were 0.31±0.09 ng/mL in the normotensive pregnant group, 0.62±0.16 ng/mL in the mild pre-eclamptic group and 0.85±0.18 ng/mL in the severe pre-eclamptic group (P<0.001). Copeptin levels in pre-eclamptic patients with abnormal Doppler velocimetry were significantly higher than in those with normal Doppler velocimetry. CONCLUSIONS: These results suggest that increased maternal levels of copeptin may be involved in the pathogenesis of pre-eclampsia and it may be useful in the assessment of the severity of the disease.
Authors: Jeremy A Sandgren; Sabrina M Scroggins; Donna A Santillan; Eric J Devor; Katherine N Gibson-Corley; Gary L Pierce; Curt D Sigmund; Mark K Santillan; Justin L Grobe Journal: Am J Physiol Regul Integr Comp Physiol Date: 2015-03-25 Impact factor: 3.619
Authors: Jeremy A Sandgren; Danny W Linggonegoro; Shao Yang Zhang; Sarah A Sapouckey; Kristin E Claflin; Nicole A Pearson; Mariah R Leidinger; Gary L Pierce; Mark K Santillan; Katherine N Gibson-Corley; Curt D Sigmund; Justin L Grobe Journal: Am J Physiol Regul Integr Comp Physiol Date: 2018-01-24 Impact factor: 3.619
Authors: Jeremy A Sandgren; Guorui Deng; Danny W Linggonegoro; Sabrina M Scroggins; Katherine J Perschbacher; Anand R Nair; Taryn E Nishimura; Shao Yang Zhang; Larry N Agbor; Jing Wu; Henry L Keen; Meghan C Naber; Nicole A Pearson; Kathy A Zimmerman; Robert M Weiss; Noelle C Bowdler; Yuriy M Usachev; Donna A Santillan; Matthew J Potthoff; Gary L Pierce; Katherine N Gibson-Corley; Curt D Sigmund; Mark K Santillan; Justin L Grobe Journal: JCI Insight Date: 2018-10-04
Authors: Sabrina M Scroggins; Donna A Santillan; Jenna M Lund; Jeremy A Sandgren; Lindsay K Krotz; Wendy S Hamilton; Eric J Devor; Heather A Davis; Gary L Pierce; Katherine N Gibson-Corley; Curt D Sigmund; Justin L Grobe; Mark K Santillan Journal: Clin Sci (Lond) Date: 2018-02-14 Impact factor: 6.124
Authors: Mark K Santillan; Donna A Santillan; Sabrina M Scroggins; James Y Min; Jeremy A Sandgren; Nicole A Pearson; Kimberly K Leslie; Stephen K Hunter; Gideon K D Zamba; Katherine N Gibson-Corley; Justin L Grobe Journal: Hypertension Date: 2014-07-07 Impact factor: 10.190